NEW ORLEANS — A higher burden of mutant TP53 cells connoted poorer risk among adults with intermediate- or high-risk myelodysplastic syndrome, according to study results presented at ASH Annual Meeting and Exposition.
A fixed-dose combination of oral decitabine and cedazuridine (Inqovi; Astex Pharmaceuticals, Taiho Oncology) may be a reasonable treatment option for these patients, findings from a post hoc analysis of the randomized phase 3 ASCERTAIN trial showed.
Survival outcomes varied between patients with biallelic vs. monoallelic mutations.
Healio spoke with researcher Guillermo